27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report issued by the Wall Street Journal, Zafgen Inc (NASDAQ: ZFGN) announced a patient fatality in the company’s beloranib study.
News of this event has crushed shares of the company, with Zafgen trading at a 57 percent discount in premarket trading to it close on Tuesday.
Anne Steele, a contributor for the Wall Street Journal, wrote, “The biopharmaceutical company said it learned Tuesday that a patient being treated with beloranib for Prader-Willi syndrome was diagnosed with bilateral pulmonary emboli—blood clots to the lung—and died...The patient was receiving the drug during the open-label extension portion of the late-stage trial, which hadn’t been halted.”
Not An Isolated Incident
This isn't the first time a patient has died in Zafgen’s beloranib study. Back in October, a patient passed away for unknown causes; subsequently the FDA put beloranib on partial clinical hold.
Zafgen’s CEO Thomas Hughes released a statement saying, “Our thoughts are with the patient and their family at this time. Patient safety remains our top priority, and we are investigating the circumstances around this event.”
Shares of Zafgen last closed at $15.93.
During pre-market trading on Wednesday, the stock priced at $6.69.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!